Empagliflozin Shows Some Potential In Type I Diabetes

Empagliflozin, for all doses investigated (2.5, 10 and 25mg), has met the primary endpoint in the EASE Phase III trial in adults with Type I diabetes. Based on the totality of the EASE data, Boehringer Ingelheim has initiated regulatory discussions for e https://www.fitchsolutions.com/corporates/healthcare-pharma/empagliflozin-shows-some-potential-type-i-diabetes-19-10-2018